C
linical trials have found transcatheter aortic valve replacement (TAVR) to be superior to medical therapy in patients with extreme surgical risk and superior or noninferior to surgical aortic valve replacement in patients with aortic stenosis who are at high and intermediate risk. [1] [2] [3] [4] [5] [6] As a result, TAVR is now the standard of care for patients with severe aortic stenosis at high or extreme risk, and a reasonable alternative in those at intermediate risk. However, there are limited comparative data on the relative performance of TAVR systems from randomized clinical trials. Data on prostheses' hemodynamic performance, regurgitation through paravalvular leak (PVL), and patients' clinical outcomes are likely to play a crucial role in the process of device selection.
The REPRISE III trial (Repositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of Lotus Valve System -Randomized Clinical Evaluation) compared a mechanically expanded, fully repositionable and retrievable valve (Lotus, Boston Scientific Corporation) with a commercially available self-expanding valve (CoreValve, Medtronic) in patients at high or extreme surgical risk. This analysis of the REPRISE III trial provides a detailed head-to-head comparison of hemodynamics and aortic regurgitation in each valve and according to valve size, and evaluates the impact of hemodynamics on clinical outcomes.
METHODS

Patient Selection and Study Design
The REPRISE III trial is a prospective, multicenter, randomized, controlled trial with noninferiority design conducted at 55 sites worldwide. 7 The study design and primary end point results have been described previously. 7 In brief, patients with symptomatic, severe native aortic stenosis (defined as aortic valve area [AVA] of ≤1.0 cm2 or AVA index of ≤0.6 cm2/m 2 and mean pressure gradient ≥40 mm Hg or jet velocity ≥4.0 m/s) were enrolled if their aortic annulus was 20 to 27 mm in diameter. Patients were required to have a Society of Thoracic Surgeons predicted risk of mortality ≥8% or another specific indicator of high-or extreme-risk status. Bicuspid valves were excluded. Patients were randomly assigned to receive the mechanically expanded Lotus Valve System (Boston Scientific Corporation) or the commercially available self-expanding CoreValve (CoreValve Classic or Evolut R, Medtronic) in a 2:1 ratio (Lotus 2:1 CoreValve). For the purpose of the present analysis, all patients enrolled in the REPRISE III trial who underwent implantation of the study device that they were randomly assigned to receive were included (Lotus n=577; CoreValve n=297).
The study is registered at ClinicalTrials.gov, unique identifier: NCT01383720. The study was approved by an institutional review board at each center, and all participants gave written informed consent. The data and analytic methods that support the findings of this study are available from the corresponding author on reasonable request and with permission of Boston Scientific Corporation. Boston Scientific Corporation sponsored this study, and the investigators had unrestricted access to the primary data for analysis and reporting of trial results.
Devices and TAVR Procedure
The test device, the Lotus Valve, consists of 3 bovine pericardial tissue valve leaflets and a braided nitinol frame with a polycarbonate-based urethane adaptive seal. 8 The control device, CoreValve, consists of a self-expanding nitinol frame and trileaflet porcine pericardial valve that is deployed with the leaflets in a supra-annular position. 3, 6 Devices were introduced via the femoral artery by using conventional percutaneous catheterization techniques. Balloon aortic valvuloplasty predilatation was followed by advancement of the valve through the aorta and aortic arch under fluoroscopic guidance. Lotus device sizes included 23-mm, 25-mm, and 27-mm diameters (recommended aortic annulus implantation range of 20-23, 23-25, and 25-27 mm, respectively); CoreValve device sizes included 26-mm, 29-mm, and 31-mm diameters (recommended aortic annulus implantation range of 20-23, 23-26, and 26-27 mm, respectively). Clinical follow-up occurred at hospital discharge or 7 days postprocedure (whichever came first), 30 days, 6 months, and 1 year, and will occur annually through 5 years.
Clinical End Points
The primary effectiveness end point of REPRISE III was the composite 1-year rate of all-cause mortality, disabling stroke, and moderate or greater paravalvular aortic regurgitation based on core laboratory assessment. Additional clinical end points were based on the Valve Academic Research Consortium (VARC)-2 end points and definitions. 9 In the primary analysis,
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• 10 were evaluated in patients implanted with different valve sizes and by discharge hemodynamics.
Transthoracic Echocardiography
Transthoracic echocardiograms were acquired at each enrolling center following a standardized acquisition protocol that was developed by the Echocardiography Core Laboratory (MedStar Health Research Institute). Echocardiograms were transferred electronically to the Echocardiography Core Laboratory for a centralized, blinded, independent analysis. Transthoracic echocardiogram analysis of the native and prosthetic aortic valves and the cardiac chambers were performed following guidelines from the American Society of Echocardiography and VARC-2. 9, [11] [12] [13] [14] Parameters measured included mean gradients (MGs) and peak pressure gradients, left ventricular outflow tract and aortic valve peak velocities, AVA, Doppler velocity index (DVI), and aortic central and paravalvular regurgitation, as well. AVA was calculated by using the continuity equation based on velocity time integral. DVI was calculated as the ratio of left ventricular outflow tract peak velocity/aortic valve peak velocity. Severity of prosthetic valve stenosis was defined according to VARC-2 criteria 9 using AVA and MG (mild stenosis if MG >20 mm Hg and AVA <1.1 cm 2 ), with the addition of DVI (<0.35) in case the first 2 were discordant. PVL was graded based on VARC-2 and Pibarot et al. 15 
Statistical Analysis
Continuous variables were estimated as mean±SD and compared with the Student t test. Discrete variables were reported as counts and percent, and differences were assessed by using χ 2 or Fisher exact tests. Time-to-event analyses were performed using the Kaplan-Meier method. Statistical analyses were performed with SAS software, version 9.2 or later.
RESULTS
Between September 22, 2014 and December 24, 2015, a total of 912 patients were randomly assigned, and 874 received the assigned valve (2:1 ratio; 577 Lotus:297 CoreValve [153 received CoreValve Classic and 144 Evolut R]), which form the population for the current report. There were no statistical differences between the 2 groups in any of the clinical baseline characteristics; data that were presented in detail in the main outcomes report are provided in Table I in the online-only Data Supplement. 7 Overall, median age was 84 (interquartile range, 9), 51% were women, and the mean Society of Thoracic Surgeons score was 6.8±4.1. Coronary artery disease was present in 72%, atrial fibrillation in 34%, and a permanent pacemaker in 18%. One-year follow-up or a VARC event occurred in 97% of cases. Echocardiograms at 1 year of follow-up were available in 88.4% of patients alive at 1 year.
Baseline echocardiographic characteristics are presented in detail in Table 1 and reflect similar populations enrolled in the Lotus and CoreValve arms (additional data can be found in Table II in the online-only Data Supplement). Left ventricular ejection fraction and dimensions, stroke volume, left atrial volume, and aortic valve hemodynamics were not different between the 2 groups. Left ventricular outflow tract and aortic annulus dimensions were also similar.
Hemodynamic Performance of Lotus and CoreValve
Gradients and Valve Area
Overall, the MG at discharge was higher in Lotus than CoreValve (12.26±5.23 versus 8.19±3.98, respectively; P<0.001), the AVA was smaller (1.64±0.47 versus 1.96±0.52, respectively; P<0.001), and the DVI (0.50±0.13 versus 0.60±0.15, respectively; P<0.001), as well. This difference diminished in subsequent echocardiograms up to 1 year ( Figure 1 ) but remained significant at all times. The hemodynamic profile by valve Table 2 and Figure 2 . Similar to the overall study population, the comparison of each valve type by size groups (small, medium, large) showed higher MG and lower AVA and DVI in the Lotus valves than in the CoreValve in all size groups (all P<0.05).
Hemodynamic Changes Over Time
Changes on the prosthetic valve hemodynamic performance over time from the early postimplant (<7 days to 30 days, 6 and 12 months in a paired comparison) are presented in Table 3 . Although change in mean gradient at 1 year was similar between the 2 groups, the AVA and DVI decreased significantly more in CoreValve than in Lotus patients, although the difference remained significant at all time points. A breakdown according to valve size is provided as Tables III and IV in the online-only Data Supplement. LV mass was similar in both groups over time and it remained unchanged both in the Lotus and CoreValve groups when comparing baseline with 1 year (Figure 1 ).
Comparison Based on VARC Performance Criteria
Considering the VARC criteria for prosthetic valve stenosis, 8.6% of the patients in the Lotus group qualified as mild stenosis at 30 days (had a MG >20 mm Hg and an AVA <1.1 cm 2 , or only one of these and a DVI <0.35) and 1.2% in the CoreValve group (P<0.001). ORIGINAL RESEARCH
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Paravalvular Leak
Although severity of aortic regurgitation at baseline was similar in both groups (P=0.10), Lotus had significantly lower rates of moderate or greater PVL than CoreValve at 12 months (overall and for each valve size, Table 4 ) and at all follow-up time points (Figure 3 
Valve Hemodynamics and Clinical Outcomes
All-cause mortality at 1 year is presented as a KaplanMeier analysis in Figure 4 and was not different between the 2 groups in any of the 3 valve sizes. The composite (Tables IV  and Table V in the online-only Data Supplement). Hospitalization for valve-related symptoms or worsening congestive heart failure (New York Heart Association class III/IV) was not different for any of the valve sizes (Table 4) . Baseline New York Heart Association class status and summary Kansas City Cardiomyopathy Questionnaire scores and their improvement through 1 year were not different between patients in Lotus and CoreValve groups treated with small, medium, or large valves (all P=not significant; Table VI in the online-only Data Supplement).
When comparing patients with normal valve gradients (<20 mm Hg, n=780) with those with abnormal gradients (>20 mm Hg, n=48) in the entire patient population, all-cause mortality was not different (10% and 12.5%, respectively; P=0.62). Prosthetic valve thrombosis occurred in 9 cases, all with the Lotus valve (1.5%; 8 with the 23-mm, 1 with the 25-mm size). Eight of the 9 thromboses were an incidental finding at the time of routine protocolmandated echocardiographic follow-up (median, 36 days; range, 26-342 days) based on elevated gradients (mean MG, 39.5 mm Hg; range, 21-60) and 1 was diagnosed after the patient presented with exertional chest pain. Six were corroborated with computed tomography or transesophageal echocardiogram (5 and 1, respectively). The remaining 3 were considered possible thrombosis based on their decrease in MG after receiving anticoagulation. None of these patients died or had a stroke. In addition to the 1 patient who had chest pain, 1 other patient had dyspnea, and the others were asymptomatic.
DISCUSSION
The current study is the first to provide a multicenter, randomized comparison of 2 contemporary TAVR devices: CoreValve, a commercially available, self-expanding valve, and Lotus, a repositionable, mechanically expandable valve. REPRISE III, therefore, provides a unique opportunity to compare the hemodynamic profile and its impact on clinical outcomes at 1 year head to head. Although the CHOICE trial (A Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: The CHOICE Trial) compared TAVR devices in the past, 16 significant differences make REPRISE III unique. CHOICE randomized earlier generations of TAVR devices and included a smaller number of patients and centers. In addition, it was powered for device success, but not for significant differences in clinical outcomes, and echocardiograms were not evaluated by a centralized core laboratory. 16, 17 This is important because TAVR has become the standard of care for patients at high or extreme surgical risk; therefore, novel TAVR devices ought to be compared with clinically approved TAVR devices. The benefit of TAVR is based on the lower morbidity and mortality of the procedures in comparison with surgical aortic valve re- 
A B placement (SAVR).
It is important to note that the hemodynamic performance of TAVR devices differs from SAVR valves in that gradients of self-expanding and balloon-expandable valves are lower, whereas their rate of significant PVL remains higher than most approved SAVR bioprosthetic valves. 1, 3, 6 Novel devices should aim at providing better clinical outcomes than SAVR with similar PVL and valve hemodynamics. In this setting, the comparison of Lotus and CoreValve in this randomized setting is unique and relevant. These findings can be summarized as follows. First, CoreValve has lower gradients and larger AVA and DVI than Lotus at discharge, a difference that tends to decrease in subsequent follow-up up to a year. Second, Lotus has lower rates of PVL, a difference that persists over time; and third, these differences are not associated with adverse clinical outcomes at 1 year.
The better hemodynamic profile of the CoreValve is not surprising, because CoreValve leaflets are placed in a supra-annular position, as opposed to the annular position of Lotus. It is important to note that both valves' hemodynamic profile compares positively with surgical bioprosthetic valves that have been widely available for use, such as the Carpentier-Edwards Perimount Magna, 18 Trifecta, 19 or Mitroflow. 20 Similar to CoreValve, balloon-expandable valves have lower gradients than those reported for Lotus here. 21 Although VARC-2 has made an attempt at defining prosthetic valve stenosis, it is important to note that a number of cases in our report would qualify as stenotic from the moment of implant, both in the Lotus and CoreValve cohorts (8.6% and 1.2%, respectively), but this stenosis does not carry an increased clinical risk at 1 year. Indeed, Douglas et al 21 has recently reported similar findings for balloon-expandable valves in a longer follow-up of 5 years. An interesting observation in our study is that CoreValve gradients increase from the initial postimplant echocardiogram to 30 days and then continue slowly increasing over time (with concomitant decrease in AVA), a finding that has been Numbers are mean±SD (n) or n/N (%) in the implanted patient population. Composite primary end point was defined as all-cause mortality, disabling stroke, and moderate or greater paravalvular leak through 1 year, hospitalization for valve-related symptoms, or worsening congestive heart failure (NYHA class III/IV). NYHA indicates New York Heart Association. 
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reported with balloon-expandable and several SAVR bioprostheses [19] [20] [21] ; MG and AVA appear to remain stable up to 1 year with the Lotus valve. This may be attributable, in part, to aortic remodeling and prosthesis recoil. The Lotus valve has a locking mechanism that prevents recoiling and may explain the better hemodynamic stability over time. The hemodynamic difference between CoreValve and Lotus in our study decreased over time up to 1 year. Therefore, one might hypothesize that the gradients and valve areas for both Lotus and CoreValve in our study will not carry an increased risk of cardiovascular events in the longer term, but 
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this is beyond the scope of this report and will be evaluated in subsequent analysis of the REPRISE III study. The lack of any clinical impact from prosthetic stenosis according to the VARC-2 criteria suggests this definition might be reevaluated. Although the early PARTNER trial (Placement of Aortic Transcatheter Valves) suggested that even mild PVL carried a higher risk of poor cardiovascular outcomes, this finding was not reproduced in subsequent multicenter studies with CoreValve or balloon-expandable valves. [22] [23] [24] [25] Also, a recent meta-analysis found that even mild PVL is associated with increased allcause and cardiovascular mortality after TAVR, 26 bringing more controversy to the importance of lower PVL rates. It is clear, however, that moderate PVL is an undesirable result after TAVR and, therefore, most manufacturers have made significant progress in their valve design to prevent PVL. The rate of moderate or greater PVL in our study is reassuring. Although it was low for the CoreValve (similar to that of the recent SURTAVI trial 4 [Surgical Replacement and Transcatheter Aortic Valve Implantation]) the rate for Lotus (0.9%) is the lowest reported for any TAVR valve so far. Although SURTAVI had a slightly lower rate of moderate or severe PVL (5.3%) in CoreValve, one must consider that echocardiograms were reviewed by a different core laboratory and that patients enrolled in SURTAVI trial were different from those enrolled in REPRISE III (intermediate versus high and extreme high risk). It is important to note that CoreValve in our study included a combination of CoreValve Classic (PVL 10.6%) and the newer generation Evolut R (PVL 2.8%), but the study was not designed or powered to compare them separately with Lotus.
Finally, it is important to note that, although statistically different, the hemodynamic performance of both CoreValve and Lotus valves was very good. Whereas CoreValve had better gradients and AVA, Lotus had better PVL rates. Overall, clinical outcomes including mortality, heart failure symptoms, quality of life, and rehospitalization were not affected by the difference in gradients or PVL.
Study Limitations
The current report reflects hemodynamic performance of the Lotus and CoreValve in the short term, because only 1 year of follow-up in REPRISE III is available at this time. Ongoing follow-up will provide this information up to at least 5 years. The control arm in the current study included 2 generations of the CoreValve (Classic and Evolut R). This situation reflects the rapidly changing standard of care attributable to the fast and steady evolution of TAVR devices. Roughly half of the patients in the CoreValve arm received each of the control valves. Although the overall findings appear to apply to both subpopulations, this study is not powered for a meaningful comparison of Lotus with each of the 2 CoreValve devices separately. Finally, it is important to note that some of the study valves used in this study are not currently available in the United States for commercial use: Lotus has not yet been considered by the Food and Drug Administration for commercial use and CV Classic was the standard of care when REPRISE III started but has been replaced by newer-generation TAVR valves.
CONCLUSIONS
The Lotus valve had significantly greater freedom from moderate or severe PVL, but a smaller valve area and higher gradients than the CoreValve. Although the hemodynamic profile was better for CoreValve, overall, both valves had favorable hemodynamics with only a small number of cases meeting criteria for mild prosthesis stenosis. The hemodynamic differences do not have a significant association with the composite end point of mortality, disabling stroke, and moderate or greater PVL at 1 year of follow-up, nor in the quality of life or heart failure symptoms.
